Multiparameter Monitors in California

Sotera Wireless develops the ViSi Mobile Patient Monitoring System, a comprehensive vital signs monitoring platform designed for continuous, real-time surveillance of patients in general care, acute care, and transport settings. The system utilizes body-worn sensors to provide noninvasive, cuff-less monitoring of blood pressure, oxygen saturation (SpO2), respiration rate, pulse, electrocardiography (ECG), patient posture, and cardiac arrhythmia detection. The platform integrates machine learning algorithms trained on millions of hours of patient data to recognize early signs of patient deterioration, including sepsis and life-threatening events, while minimizing false alarms and alert fatigue. Data streams directly into electronic medical records (EMR) systems, enabling clinicians to detect critical changes between scheduled vital sign checks and respond with rapid intervention. The system is designed for ambulatory patients, those in transport, and bedside monitoring, providing continuous surveillance with enhanced clinical workflow integration. The ViSi Mobile platform emphasizes patient safety through early warning systems that address the clinical gap where dangerous deterioration can occur during intervals between conventional spot-check vital sign assessments.

MedWand Solutions is a US-based telehealth device and software company specializing in remote patient examination and vital sign capture. The company manufactures the MedWand Multi-Sensor Device, an FDA 510(k)-cleared hardware platform that enables clinicians to conduct comprehensive physical exams remotely via WiFi or cellular networks. The device captures 10+ clinical-grade biometrics including temperature, blood pressure, oxygen saturation, heart and lung sounds, ECG, otoscope images, and skin imaging. MedWand's VirtualCare Telemedicine Platform integrates with existing EHR and patient management systems through REST API and supports CMS interoperability standards. The platform serves rural clinics, home health, employer on-site programs, substance-use clinics, decentralized clinical trials, and disaster response operations. MedWand emphasizes "treat-in-place" workflows to reduce unnecessary ER transfers and readmissions while lowering healthcare delivery costs. The company offers standalone kiosk deployment options requiring no EHR integration. Third-party Bluetooth device integration allows connection to external blood pressure monitors, glucometers, and weight scales. Key markets include primary care, transitional care, payers seeking HEDIS improvement, and international telehealth expansion (demonstrated operations in Thailand and Rwanda).

Ventric Health manufactures the Vivio® System, an FDA-cleared Class II medical device for non-invasive heart failure diagnosis in primary care settings. The Vivio System uniquely measures left ventricular end-diastolic pressure (LVEDP)—the clinical hallmark of heart failure—using a portable, point-of-care approach combining brachial cuff and ECG technology. The system delivers results in under five minutes and integrates the Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) to assess patient symptoms and disease burden. Approximately 70% of patients identified with elevated LVEDP exhibit Stage C heart failure symptoms, while 30% present Stage B findings. The Vivio System demonstrates superior specificity and sensitivity compared to traditional clinical indicators, enabling clinicians to identify at-risk patients earlier and initiate guideline-directed medical therapy more promptly. Target markets include primary care physicians, cardiologists, Medicare ACOs, healthcare systems, and Medicare Advantage plans. The company has established partnerships with leading health systems including Agilon Health, AltaMed, Desert Oasis Healthcare, Heritage Victor Valley Medical Group, and Regal Medical Group. Ventric Health is based in Pasadena, California, and operates through clinical validation studies published in peer-reviewed journals including JACC: Advances and the Journal of the American Heart Association.

Piccolo Medical designs and manufactures guidance systems for peripherally inserted central catheter (PICC) and central venous catheter (CVC) placement. The company's flagship products—PM2+™ System and ECGuide®—use intravascular electrocardiogram (ECG) technology combined with ionic dilution sensing to enable bedside confirmation of catheter tip positioning, eliminating the need for post-placement chest X-ray confirmation. The PM2+™ System features the Nav+™ stylet with machine learning-powered navigation feedback delivered via a mobile app; setup takes under 90 seconds and provides real-time guidance during catheter insertion. ECGuide® is cleared for use in adult, pediatric, and neonatal patients and has been shown to improve placement accuracy and reduce complications including thrombosis and malposition. The technology addresses a significant clinical and operational problem: approximately 50% of PICCs placed without guidance are malpositioned, requiring confirmatory imaging that adds cost, radiation exposure, and procedure time (average 78-minute wait for chest X-ray). Piccolo Medical is FDA 510(k) cleared and has received funding from the National Institute on Aging (NIA) and other federal agencies. The company serves hospitals and healthcare systems focused on improving catheter placement safety and reducing procedural delays.

Masimo Corporation is a global leader in noninvasive patient monitoring solutions, specializing in innovative pulse oximetry, vital sign monitoring, and brain function monitoring technologies. Founded on breakthrough accuracy in pulse oximetry (Masimo SET®), the company develops and manufactures continuous monitoring systems for hospitals, ICUs, operating rooms, and neonatal care settings. Core product lines include Masimo SET® Pulse Oximetry for continuous, accurate oxygen saturation measurement across all patient populations and clinical settings; SedLine® Brain Function Monitoring for depth-of-anesthesia and sedation monitoring; Masimo O3® Regional Oximetry for tissue oxygenation assessment with FDA-cleared hemoglobin parameters; and Root® Patient Monitoring and Connectivity Platform, a modular hospital automation system integrating vital signs, connectivity, and clinical workflow solutions. Masimo technologies are deployed across acute care, perioperative, emergency, neonatal, and general floor environments. The company holds over 900 patents globally and serves leading hospitals and healthcare systems in 30+ countries. Known for motion-artifact rejection and performance accuracy across diverse patient populations, Masimo's solutions address clinical needs in congenital heart disease screening, critical care monitoring, anesthesia management, and cost reduction through early patient distress detection. The company emphasizes sustainability and has strategic partnerships with major healthcare technology providers including Philips. Acquired by Danaher in February 2026.

LifeSignals, Inc. is a medical device company specializing in wireless patient monitoring solutions and disposable wearable biosensors for in-hospital, hospital-at-home, and ambulatory care settings. The company develops the UbiqVue™ platform, a cloud-based wireless patient monitoring system that captures continuous vital signs including 2-channel ECG and multiparameter vital signs through single-use, cost-effective biosensors. LifeSignals' patented LSP silicon platform enables disposable sensors designed for mass production, reducing clinical device costs while maintaining clinical-grade accuracy. The UbiqVue Multiparameter system provides near real-time vital sign monitoring for large-scale in-hospital and hospital-at-home delivery; the UbiqVue Holter system delivers cloud-based ECG analysis and reporting for ambulatory cardiac services and mobile cardiac telemetry (MCT). Core technology includes Wi-Fi-centric wireless connectivity with support for multiple radios, HIPAA and GDPR-compliant data transfer, and robust encryption. The company serves healthcare providers, integrated delivery networks, and digital health platforms seeking to untether patients from wired monitoring constraints while enabling data-driven clinical insights. LifeSignals operates manufacturing and integration capabilities with headquarters in Milpitas, CA, and regional offices in India, Europe (Ireland), and Asia-Pacific (Singapore), supporting global deployment of wireless healthcare monitoring infrastructure across population health initiatives.

Universal Diagnostic Solutions (UDS) is an FDA-registered medical device distributor and reseller specializing in new, pre-owned, refurbished, and demo ultrasound imaging systems and complementary diagnostic medical equipment. With over 15 years of experience, UDS represents all major ultrasound manufacturers including GE, Philips, Mindray, Sonosite, Samsung, and Terason. The company provides a full-service model encompassing sales consultation, equipment customization, installation, operator training, and ongoing technical support. Product portfolio includes portable and console-based ultrasound systems, C-arm fluoroscopy X-ray equipment, vital signs monitors (NIBP, SpO2, temperature), patient examination tables (partnered with Oakworks for abdominal, musculoskeletal, vascular, and biopsy applications), and automated external defibrillators (AEDs). UDS serves diverse markets including private practices, academic medical centers, veterinary sonography, osteopathic schools, and rehabilitation clinics. The company operates a warehouse facility in Vista, California, and offers nationwide distribution with localized support through manufacturer partnerships (Mindray and Edan maintain US service locations). UDS is compliant with California State Board of Pharmacy regulations and authorized to sell Class II medical devices. The company emphasizes personalized customer engagement, rapid service turnaround, competitive pricing strategies (advertising 40% discounts on console systems), and extensive product knowledge to assist buyers in navigating the complex diagnostic imaging marketplace.

Aulisa Medical is a Palo Alto, CA-based medical device company founded in 2012 that develops FDA-cleared, wireless wearable patient monitoring systems for continuous vital sign tracking in clinical and home environments. The company specializes in cloud-based remote monitoring solutions utilizing artificial intelligence to detect inconsistencies in vital sign data and enable early intervention for potentially adverse events. Products are designed for infants, children, and adults across multiple care settings. The Guardian Angel® product line serves as the primary offering, functioning as both a consumer baby monitor and clinical-grade vital sign monitoring device. Applications include monitoring for sleep safety, chronic respiratory diseases (COPD, sleep apnea), cardiac conditions, post-procedure recovery, and aging-in-place scenarios. The company addresses the need to reduce manual vital sign spot-checking burden for both clinicians and caregivers through automated, continuous monitoring with alert capabilities. Aulisa has achieved FDA clearance for its devices and is backed by Silicon Valley venture capital investors. The company operates both direct-to-consumer and hospital/clinical distribution channels, with products available for in-home use and institutional hospital settings.

EdanUSA is a San Diego-based distributor and service center for FDA-approved diagnostic medical equipment, established in 2009 to provide U.S. local support and inventory. The company stocks over $1 million in diagnostic equipment and spare parts, serving over 100 resellers across the United States. EdanUSA specializes in high-quality, cost-effective diagnostic devices including patient monitors, ECG/EKG machines, ultrasound systems, fetal monitors, Holter monitors, pulse oximeters, colposcopes, Dopplers, and vital sign monitoring equipment. All products are backed by a three-year manufacturer warranty with on-site customer service and factory-trained engineers guaranteeing 24-48 hour service turnaround. The company offers pricing 30-40% below major U.S. competitors while maintaining comprehensive support through a dedicated service center, learning resources, and EMR connectivity assistance.

FaceHeart Corporation develops FDA-cleared contactless video-based vital signs measurement software powered by artificial intelligence image recognition technology. The company's flagship product, FaceHeart Vitals™ (registered as FH Vitals SDK), is a Software as Medical Device (SaMD) that measures multiple vital parameters from a 50-second facial scan without requiring wearables or connected devices. The solution has received two FDA 510(k) Class II clearances: one for Heart Rate measurement (k223622) and one for Respiration Rate measurement (k243966). The platform measures heart rate, respiration rate, blood pressure, oxygen saturation, heart rate variability, stress index, and screens for atrial fibrillation. Additional biomarkers in beta development include HbA1c, hemoglobin, and cholesterol. FaceHeart Vitals™ is designed for seamless integration with diverse devices and platforms including mobile phones, laptops, desktops, digital picture frames, smart TVs, smart mirrors, security cameras, and robots, eliminating the need for proprietary hardware. Primary applications span telemedicine and remote healthcare (enabling spot checks, diagnostics, and triage), digital health and wellness applications, and smart device integration for both medical and consumer settings. The technology provides medical-grade accuracy trained on millions of datasets and is compatible with various platforms and operating systems. FaceHeart serves healthcare providers, telemedicine platforms, digital health application developers, and smart device manufacturers seeking to integrate contactless vital sign monitoring. The company has garnered industry recognition, including selection for the Forbes Asia 100 to Watch 2025 list and the MedTech Breakthrough Awards 2025 for Best Biometric Sensor Solution.